摘要:
The present invention is directed to methods and kits for measurement of cis-diols in a sample by means of dyes which produce a spectral change upon reaction or complexation with cis-diols. The present invention is also directed to solid supports having such dyes as substituents thereon. In particular, measurement of glucose using azo boronic dyes is disclosed.
摘要:
A thermal lithographic printing plate overcoat composition comprising (a) a water- soluble polymeric dye having an absorption band between about 300 and about 600 nm; and (b) micro-particles or nano-particles is provided. A negative-working thermal lithographic printing plate comprising (a) a hydrophilic substrate; (b) a near infrared imaging layer disposed on the hydrophilic substrate; and (c) an overcoat layer disposed on the imaging layer, said overcoat layer comprising a water-soluble polymeric dye having an absorption band between about 300 and about 600 nm; and micro-particles or nano-particles is also provided. Finally, a water-soluble polymeric dye having an absorption band between about 300 and about 600 nm is provided.
摘要:
Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.
摘要:
Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.
摘要:
The presence and location of amyloid deposits in an organ or body area of a patient is effected by intravenous administration of novel radioactive iodine-labeled amyloid binding compounds and preferably ¹²³I-labeled compounds to the patient and sensing radiation emitted from the organ or body area. Novel non-radioactive iodine substituted amyloid binding compounds and amyloid binding compounds which are readily iodinated are further aspects or the invention.